

Primary cutaneous marginal zone lymphoma in a patient with multiple sclerosis under fingolimod therapy

Thilo Gambichler,¹⁻³ Sera Selina Weyer-Fahlbusch,¹ Markus Werner,¹ Ulrika Schade,⁴ Lieselotte Bissels,⁵ Laura Susok²

¹Department of Dermatology, Dortmund Hospital gGmbH, Witten-Herdecke University, Dortmund; ²Department of Dermatology, Christian Hospital, Unna; ³Department of Dermatology, Ruhr-University Bochum; ⁴Hematopathology Lübeck Center; ⁵Department of Neurology, Dortmund Hospital gGmbH, Witten-Herdecke University, Dortmund, Germany

Key words: lymphoma; B cell lymphoma; fingolimod; sphingosine-1-phosphate receptor antagonist; T cell lymphoma.

Correspondence: Thilo Gambichler, Dortmund Hospital gGmbH, Witten-Herdecke University, Dortmund, Germany.
E-mail: t.gambichler@klinikum-bochum.de

Dear Editor,

Increased prevalence of cancer, in particular lymphomas, has been observed in patients with multiple sclerosis (MS) treated with fingolimod.¹⁻⁷ We report the first case of primary cutaneous marginal zone lymphoma (PCMZL) that developed under long-term fingolimod therapy for MS.

A 54-year-old female presented with a 22-year history of relapsing-remitting MS, initially treated with glatiramer acetate followed by interferon- β 1. In 2016, the patient started receiving fingolimod because of progressive disease. In the summer of 2024, she developed several asymptomatic, brownish-erythematous nodules on her upper legs, buttocks, and left upper arm (Figure 1). At this time, she was taking fingolimod 0.5 mg/d, while her MS was graded 6.0 according to the Expanded Disability Status Scale. An elliptical excision of one lesion on the right upper left leg was performed for histological examination. Histopathology revealed a dense, nodular dermal infiltrate, as well as a sparse infiltrate, sometimes organized in follicular structures, sparing the epidermis, consisting of small lymphocytes and plasma cells (Figure 2). The immunohistochemistry stain revealed dense CD20⁺ B cell aggregates, follicular-like structures with positivity for CD23, and only weak CD10 expression with negativity for B-cell lymphoma 2. Plasma cells also showed kappa light-chain restriction and reactivity to CD138 (Figure 2). According to the BIOMED-2 protocol, we observed a small Ig kappa (tube A) amplicon of 284 bp and an Ig kappa (tube B) amplicon of 282 bp. Low expression of 10% for Ki-67 was detected. Polymerase chain reaction testing was negative for *Borrelia burgdorferi* and positive for Epstein-Barr virus (EBV). However, EBV-encoded small RNAs (EBER) *in situ* hybridization as well as LMP1 immunohistochemistry of tumor tissue were negative. A diagnosis of PCMZL was made.

Complete blood count revealed severe lymphopenia of 160/ μ l (110-4500). Serology for *B. burgdorferi* was negative. Immune electrophoresis, including immune fixation, did not reveal evidence for monoclonal gammopathy and Bence Jones proteinuria. A blood smear was unremarkable. Flow cytometry of lymphocytic subpopulations in the peripheral blood was unremarkable. Lymph node ultrasound, neck, thorax, and abdomen computed tomography, and cranial magnetic resonance imaging did not reveal evi-

dence for lymphoma manifestation in other organs but the skin. Because of the indolent nature of PCMZL, we refrained from bone marrow biopsy. Hence, fingolimod was discontinued, and ofatumumab was initiated.

Ofatumumab is a fully human IgG1 monoclonal anti-CD20 antibody. It is approved for the treatment of MS with a subcutaneous dose of 20 mg at weeks 0, 1, and 2, followed by 20 mg once monthly from week 4.⁷

The result of a recent meta-analysis demonstrated that the pooled prevalence of malignancies in MS patients who received fingolimod was 2%.¹ About 20 cases of fingolimod-induced lymphoma in MS patients have been published, the majority represented by T cell lymphomas, in particular, primary cutaneous CD30⁺ anaplastic large T cell lymphoma, lymphomatoid papulosis, and mycosis fungoides.¹ Hence, most lymphoproliferative diseases were observed in the skin but more rarely also in the bladder, eye, mediastinum, and central nervous system. To the best of our knowledge, this is the third published case of a primary cutaneous B-cell lymphoma developing during fingolimod therapy.^{2,5,6} In the present case, lymphoma development was relatively late. However, regarding the timing of the onset of fingolimod-induced lymphomas in MS patients, there is great variability. Interestingly, a potential causal relationship between drug administration and lymphoma development has been suggested, as lymphomas have not only emerged during fingolimod therapy but, in one case report, also showed spontaneous regression following fingolimod discontinuation, though the reported follow-up was limited to only four weeks.⁴ Moreover, animal models have demonstrated that fingolimod predisposes to lymphoma development by reducing immune surveillance of neoplastic lymphoid clones in the periphery through modulation of the peripheral T lymphocytic microenvironment.³ Fingolimod is capable of inhibiting lymphocyte egress from lymph nodes through the modulation of sphingosine-1-phosphate receptors and thereby prevents lymphocyte migration to peripheral tissues. Furthermore, fingolimod is capable of inducing differentiation of peripheral T cells towards a regulatory T lymphocyte phenotype and blocks antigen presentation by inhibiting Langerhans cell migration to lymph nodes. However, it is unclear why fingolimod appears to be most frequently associated with primary cutaneous CD30⁺ T cell lymphomas rather than other extra-



Figure 1. Slightly reddish palpable subcutaneous nodule on the thigh of a patient with multiple sclerosis and primary cutaneous marginal zone lymphoma developed under fingolimod therapy.

nodal lymphoproliferative diseases also known to originate from tissue-resident memory T cells.³

Given the established association between fingolimod and cutaneous malignancies, regular dermatologic surveillance is recommended. This case underscores the importance of raising awareness among dermatologists that patients receiving fingolimod may also be at increased risk for developing cutaneous B-cell lymphomas, in addition to the more commonly reported T-cell variants.

References

1. Askari M, Mirmosayyeb O, Ghaffary EM, et al. Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis. *Mult Scler Relat Disord* 2022;59:103680.
2. Wills A, Fan G, Kim E, et al. Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod. *Dermatol Online J* 2019;25:13030/qt2g62q2fq.
3. Connolly A, Grandi V, Stefanato CM, et al. Primary cutaneous CD30⁺ anaplastic large-cell lymphoma associated with fingolimod. *Br J Dermatol* 2018;179:1400-1.
4. Froehlich A, Schmidt S, Landsberg J, et al. Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. *Mult*




Figure 2. Hematoxylin-eosin stain of a skin biopsy revealed a sparse infiltrate sometimes organized in follicular structures (a, magnification x100) consisting of small lymphocytes and plasma cells (b, magnification x250; c, magnification x400). Immunohistochemically (c), the infiltrating lymphocytes were strongly positive for kappa (d) and only partially positive for lambda (e, magnification x100).

- Scler 2018;24:1785-7.
5. Soma L, Crisan L, Reid J, et al. Epstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature. Am J Clin Pathol 2024;aqae124.
 6. Stitt DW, Boes CJ, Flanagan EP, et al. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler Relat Disord 2018;19:115-7.
 7. Awada Z, Hameed N, Harel A. Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. Drug Des Devel Ther 2024;18:5985-96.

Received: 24 December 2024; Accepted: 17 May 2025.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: no ethical committee approval was required for this case report by the Department, because this article does not contain any studies with human participants or animals. Informed consent was obtained from the patient included in this study.

Consent for publication: written informed consent for publication of clinical details and clinical images was obtained from the patient.

Availability of data and materials: all data generated or analyzed during this case study are included in this published article.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).